Vertex Pharmaceuticals Inc
VRTX
NASDAQ
Biotechnology
$505.75
USD
-10.69 (-2.07%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $135.24B
Volume 1.1M
Revenue
$12.59B
TTM
+10.2%
YoY
Gross Margin
86%
TTM
-0.1%
YoY
Net Income
$4.41B
TTM
+21.1%
YoY
Operating Cash Flow
$4.29B
TTM
+11.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2,964.7 | 3,076.4 | 3,190.0 | 2,986.9 | 3,333.9 |
YoY Growth | +12.1% | +11.0% | +9.5% | +7.8% | +12.5% |
Cost of Revenue | 407.5 | 414.8 | 466.0 | 392.8 | 489.2 |
Gross Profit | 2,557.2 | 2,661.6 | 2,724.0 | 2,594.1 | 2,844.7 |
Selling, General & Administrative | 424.6 | 445.1 | 487.0 | 493.7 | 582.2 |
Other Operating Expenses | 3.1 | 52.6 | 57.4 | 0.7 | 21.8 |
Total Operating Expenses | 1,406.1 | 1,475.4 | 1,518.1 | 1,456.0 | 1,597.8 |
Operating Income | 1,151.1 | 1,186.2 | 1,205.9 | 1,138.1 | 1,246.9 |
EBITDA | 1,205.0 | 1,294.7 | 1,318.1 | 1,194.7 | 1,324.8 |
Other Income / Expense | 13.2 | -9.8 | 6.5 | 0.0 | 24.3 |
Total Other Income / Expense | 131.9 | 112.6 | 125.1 | 114.8 | 144.9 |
Income Before Income Taxes | 1,283.0 | 1,298.8 | 1,331.0 | 1,252.9 | 1,391.8 |
Income Taxes | 250.1 | 215.9 | 139.9 | 221.5 | 292.0 |
Net Income | 1,032.9 | 1,082.9 | 1,191.1 | 1,031.4 | 1,099.8 |
Consolidated Net Income / Loss | 1,032.9 | 1,082.9 | 1,191.1 | 1,031.4 | 1,099.8 |
Net Income Attributable to Common Shareholders | 1,032.9 | 1,082.9 | 1,191.1 | 1,031.4 | 1,099.8 |
Basic EPS | $4.02 | $4.24 | $4.70 | $4.06 | $4.34 |
Diluted EPS | $3.99 | $4.20 | $4.65 | $4.02 | $4.31 |
Basic Shares Outstanding | 256.7M | 255.6M | 253.6M | 254.1M | 253.7M |
Diluted Shares Outstanding | 258.9M | 257.6M | 256.0M | 256.3M | 255.2M |